Compare BEAM & TENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAM | TENB |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2020 | 2018 |
| Metric | BEAM | TENB |
|---|---|---|
| Price | $31.65 | $22.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 18 |
| Target Price | ★ $46.00 | $38.12 |
| AVG Volume (30 Days) | ★ 2.0M | 1.4M |
| Earning Date | 02-24-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $55,701,000.00 | ★ $974,603,000.00 |
| Revenue This Year | N/A | $12.22 |
| Revenue Next Year | $26.52 | $7.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.05 |
| 52 Week Low | $13.53 | $21.55 |
| 52 Week High | $36.44 | $45.45 |
| Indicator | BEAM | TENB |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 37.91 |
| Support Level | $29.80 | $21.55 |
| Resistance Level | $35.34 | $23.35 |
| Average True Range (ATR) | 2.80 | 0.62 |
| MACD | 0.14 | 0.07 |
| Stochastic Oscillator | 55.79 | 44.42 |
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.